Home Cart Sign in  
Chemical Structure| 1903783-48-1 Chemical Structure| 1903783-48-1

Structure of TK216
CAS No.: 1903783-48-1

Chemical Structure| 1903783-48-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

TK-216, an analog of YK-4-279 inhibitor, is a potent and selective EWS-FLI1 inhibitor. TK-216 is in early clinical development for the treatment of Ewing sarcoma.

Synonyms: ONCT 216; SPH-8216

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of TK216

CAS No. :1903783-48-1
Formula : C19H15Cl2NO3
M.W : 376.23
SMILES Code : O=C1NC2=C(C(Cl)=CC=C2Cl)C1(CC(C3=CC=C(C4CC4)C=C3)=O)O
Synonyms :
ONCT 216; SPH-8216
MDL No. :MFCD32690095
InChI Key :ZWHNLSHDLKIXOG-UHFFFAOYSA-N
Pubchem ID :121268274

Safety of TK216

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of TK216

DNA

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
RDES RDES To evaluate the effect of TK216 as an adjuvant drug in long-term 2D cell culture. Results showed that TK216 was statistically active across all four EWS cell lines. Sci Rep. 2023 Sep 1;13(1):14360.
SK-ES-1 SK-ES-1 To evaluate the effect of TK216 as an adjuvant drug in long-term 2D cell culture. Results showed that TK216 was statistically active across all four EWS cell lines. Sci Rep. 2023 Sep 1;13(1):14360.
SK-N-MC SK-N-MC To evaluate the effect of TK216 as an adjuvant drug in long-term 2D cell culture. Results showed that TK216 was statistically active across all four EWS cell lines. Sci Rep. 2023 Sep 1;13(1):14360.
A673 A673 To evaluate the effect of TK216 as an adjuvant drug in long-term 2D cell culture. Results showed that TK216 was statistically active across all four EWS cell lines. Sci Rep. 2023 Sep 1;13(1):14360.
REH REH TK216 induced growth inhibition, cell cycle arrest and apoptosis and inhibited the migratory capability of leukemic cells. Genes (Basel). 2023 Oct 8;14(10):1916.
KOPN-8 KOPN-8 TK216 induced growth inhibition, cell cycle arrest and apoptosis and inhibited the migratory capability of leukemic cells. Genes (Basel). 2023 Oct 8;14(10):1916.
SUP-B15 SUP-B15 TK216 induced growth inhibition, cell cycle arrest and apoptosis and inhibited the migratory capability of leukemic cells. Genes (Basel). 2023 Oct 8;14(10):1916.
THP-1 THP-1 TK216 induced growth inhibition, cell cycle arrest and apoptosis and inhibited the migratory capability of leukemic cells. Genes (Basel). 2023 Oct 8;14(10):1916.
MV4-11 MV4-11 TK216 induced growth inhibition, cell cycle arrest and apoptosis and inhibited the migratory capability of leukemic cells. Genes (Basel). 2023 Oct 8;14(10):1916.
REH REH TK216 induced growth inhibition, cell cycle arrest and apoptosis and inhibited the migratory capability of leukemic cells. Genes (Basel). 2023 Oct 8;14(10):1916.
KOPN-8 KOPN-8 TK216 induced growth inhibition, cell cycle arrest and apoptosis and inhibited the migratory capability of leukemic cells. Genes (Basel). 2023 Oct 8;14(10):1916.
MOLT4 cells MOLT4 cells Suppressed SLFN11 expression iScience. 2021 Sep 25;24(10):103173.
SUP-B15 SUP-B15 TK216 induced growth inhibition, cell cycle arrest and apoptosis and inhibited the migratory capability of leukemic cells. Genes (Basel). 2023 Oct 8;14(10):1916.
THP-1 THP-1 TK216 induced growth inhibition, cell cycle arrest and apoptosis and inhibited the migratory capability of leukemic cells. Genes (Basel). 2023 Oct 8;14(10):1916.
MV4-11 MV4-11 TK216 induced growth inhibition, cell cycle arrest and apoptosis and inhibited the migratory capability of leukemic cells. Genes (Basel). 2023 Oct 8;14(10):1916.
CD8+ OT-I T cells CD8+ OT-I T cells To evaluate the effect of TK216 on cytokine production in CD8+ T cells, results showed TK216 inhibited cytokine production in Tet2KO CD8+ T cells. Cancer Res. 2021 Apr 15;81(8):1965-1976.
B16-OVA mouse melanoma cells B16-OVA mouse melanoma cells To evaluate the effect of TK216 on B16-OVA cell apoptosis, results showed TK216 significantly reduced B16-OVA cell apoptosis induced by Tet2KO CD8+ T cells. Cancer Res. 2021 Apr 15;81(8):1965-1976.
REH cells REH cells To evaluate the effect of TK216 on REH cell viability, results showed significant reduction in cell viability and proliferation Genome Med. 2020 Nov 20;12(1):99.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
NOD/SCID/IL2gr-null mice EWS xenograft model Intraperitoneal injection 25 mg/kg or 50 mg/kg Once daily for 37 days To evaluate the effect of TK216 as an adjuvant drug in the EWS xenograft model. Results showed that TK216 exhibited antitumor activity at both 25 mg/kg and 50 mg/kg doses, but the 50 mg/kg dose group showed toxicity (weight loss) and treatment-related mortality. Sci Rep. 2023 Sep 1;13(1):14360.

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02657005 Sarcoma, Ewing PHASE1|PHASE2 TERMINATED 2025-06-22 UCLA Jonsson Comprehensive Can... More >>cer Center, Los Angeles, California, 90095, United States|Children's Hospital of Colorado, Aurora, Colorado, 80045, United States|Children's National Hospital, Washington, District of Columbia, 20010, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10174, United States|Duke Cancer Institute, Durham, North Carolina, 27710, United States|Cleveland Clinic Foundation, Cleveland, Ohio, 44195, United States|Oregon Health & Science University, Portland, Oregon, 97239, United States|Texas Children's Cancer & Hematology Centers, Baylor College, Houston, Texas, 77030, United States|UT MD Anderson Cancer Center, Houston, Texas, 77030, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.66mL

0.53mL

0.27mL

13.29mL

2.66mL

1.33mL

26.58mL

5.32mL

2.66mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories